<p>加利福尼亞州埃默裏維爾 --（商業資訊）--Estrella Immunopharma, Inc.（納斯達克：ESLA，ESLAW）（“公司”）是一家臨牀階段的生物製藥公司，開發針對 CD19 和 CD22 的 ARTEMIS T 細胞療法，以治療癌症和自身免疫疾病。今天，公司宣佈與一家專注於醫療保健的機構投資者完成之前宣佈的註冊直接發行，發行和出售 4,063,290 股公司普通股和 1,000,000 個預先融資的認股權證。在同時進行的私募中，公司向投資者發行並出售了可購買最多 7,594,935 股普通股的普通認股權證。</p>
<p>每股普通股及其附帶認股權證的綜合發行價格為 1.58 美元（或每個預先融資的認股權證及其附帶認股權證為 1.57999 美元）。預先融資的認股權證的行使價格為每股 0.00001 美元，發行後可立即行使，且在完全行使之前不會到期。普通認股權證的行使價格為每股 1.39 美元，發行後可行使，並將在首次行使日期的第五個週年到期。</p>
<p>交易於 2026 年 1 月 6 日完成，約獲得 800 萬美元的總毛收益。公司預計將利用此次發行的淨收益以及現有現金用於一般企業用途和營運資金。</p>
<p>“此次融資的成功完成凸顯了投資者對我們臨牀願景的持續支持，併為 Estrella 提供了額外資源，以追求我們的臨牀目標，” Estrella 的總裁兼首席執行官劉成博士表示。“我們已做好充分準備，推動我們的主導項目 EB103 進入第二階段試驗，並朝着關鍵的價值提升點邁進。我們相信這是為不符合當前市場療法的患者開發我們的 ARTEMIS® T 細胞療法的關鍵一步。”</p>
<p><strong>Aegis Capital Corp.擔任此次發行的獨家配售代理。Winston &amp; Strawn LLP 擔任公司的法律顧問。Sichenzia Ross Ference Carmel LLP 擔任 Aegis Capital Corp.的法律顧問。</strong></p>
<p>上述證券（不包括普通認股權證及其基礎的普通股）是根據美國證券交易委員會（“SEC”）於 2024 年 12 月 19 日宣佈生效的 S-3 表格的架構註冊聲明（文件編號 333-283770）進行的。註冊直接發行僅通過招股説明書進行，包括招股説明書補充，這是有效註冊聲明的一部分。最終招股説明書補充及其附帶招股説明書的電子副本可在 SEC 網站 http://www.sec.gov 上獲取，或通過聯繫 Aegis Capital Corp.，注意：承銷部，1345 Avenue of the Americas，27 樓，紐約，NY 10105，電子郵件：syndicate@aegiscap.com，或電話：+1 (212) 813-1010。</p>
<p>普通認股權證在同時進行的私募中的發行和銷售是非公開發行的交易，未根據 1933 年證券法（“證券法”）或適用的州證券法進行註冊。因此，普通認股權證及其基礎的普通股在美國不得重新發行或轉售，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免。證券僅向合格投資者提供。根據與投資者的註冊權協議，公司已同意向 SEC 提交一份或多份註冊聲明，涵蓋根據普通認股權證行使後可出售的普通股。</p>
<p>在投資此發行之前，感興趣的各方應全面閲讀招股説明書補充及其附帶招股説明書，以及公司向 SEC 提交的其他文件，這些文件已在該招股説明書補充及其附帶招股説明書中引用，提供有關公司及該發行的更多信息。</p>
<p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的要約、徵求或銷售在註冊或資格之前是非法的。</p>
<p><strong>關於 Estrella Immunopharma, Inc.</strong></p>
<p>Estrella 是一家臨牀階段的生物製藥公司，開發針對 CD19 和 CD22 的 ARTEMIS T 細胞療法，以治療癌症和自身免疫疾病。Estrella 的使命是利用人類免疫系統的進化力量，改變與癌症和其他疾病作鬥爭的患者的生活。為實現這一使命，Estrella 的主打產品候選 EB103 利用 Eureka 的 ARTEMIS 技術，針對 CD19，這是一種幾乎在所有 B 細胞白血病和淋巴瘤表面表達的蛋白質。Estrella 還在開發 EB104，該產品同樣利用 Eureka 的 ARTEMIS 技術，不僅針對 CD19，還針對 CD22，這是一種與 CD19 相似，在大多數 B 細胞惡性腫瘤表面表達的蛋白質。</p>
<p><strong>前瞻性聲明</strong></p>
<p>上述材料可能包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條（均已修訂）定義的 “前瞻性聲明”。前瞻性聲明包括所有不單純與歷史或當前事實相關的聲明，包括但不限於關於公司的產品開發和商業前景的聲明，並且可以通過使用 “可能”、“將”、“期望”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛在”、“應該”、“繼續” 或這些詞的否定形式或其他可比詞彙來識別。前瞻性聲明並不保證未來的行動或表現。這些前瞻性聲明是基於公司當前可獲得的信息及其當前計劃或預期，並且受到可能顯著影響當前計劃的多種風險和不確定性的制約。如果這些風險或不確定性中的一個或多個變為現實，或者基礎假設被證明不正確，實際結果可能與預期、相信、估計、期望、意圖或計劃的結果有顯著差異。儘管公司相信前瞻性聲明中反映的期望是合理的，但公司無法保證未來的結果、表現或成就。除非適用法律（包括美國的證券法）要求，否則公司不打算更新任何前瞻性聲明以使這些聲明與實際結果一致。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ"/></p>
<p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260106009556/en/</p>
<p>投資者關係</p>
<p>Estrella Immunopharma, Inc.</p>
<p>IR@estrellabio.com</p>
<p>來源：Estrella Immunopharma, Inc.</p>

ESLA

<p>Estrella Immunopharma, Inc. 已完成 800 萬美元的註冊直接發行和同時的私募配售，發行了 4,063,290 股普通股和 1,000,000 個預融資認股權證。發行價格為每股 1.58 美元，預融資認股權證可立即行使。這筆資金將支持公司的臨牀目標，特別是推動其主導項目 EB103 進入第二階段臨牀試驗。Aegis Capital Corp. 擔任獨家配售代理。該證券是在一個貨架註冊聲明下發行，僅面向合格投資者</p>

<p>EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants. In a concurrent private placement, the Company issued and sold to the investor common warrants to purchase up to an aggregate of 7,594,935 shares of common stock.</p>
<div class="lb-trans"><p>加利福尼亞州埃默裏維爾 --（商業資訊）--Estrella Immunopharma, Inc.（納斯達克：ESLA，ESLAW）（“公司”）是一家臨牀階段的生物製藥公司，開發針對 CD19 和 CD22 的 ARTEMIS T 細胞療法，以治療癌症和自身免疫疾病。今天，公司宣佈與一家專注於醫療保健的機構投資者完成之前宣佈的註冊直接發行，發行和出售 4,063,290 股公司普通股和 1,000,000 個預先融資的認股權證。在同時進行的私募中，公司向投資者發行並出售了可購買最多 7,594,935 股普通股的普通認股權證。</p>
</div><p>The combined offering price for each share of common stock and accompanying warrant was $1.58 (or $1.57999 with respect to each pre-funded warrant and accompanying warrant). The pre-funded warrants have an exercise price of $0.00001 per share, are exercisable immediately upon issuance, and will not expire until fully exercised. The common warrants have an exercise price of $1.39 per share, are exercisable upon issuance and will expire on the fifth anniversary of the initial exercise date.</p>
<div class="lb-trans"><p>每股普通股及其附帶認股權證的綜合發行價格為 1.58 美元（或每個預先融資的認股權證及其附帶認股權證為 1.57999 美元）。預先融資的認股權證的行使價格為每股 0.00001 美元，發行後可立即行使，且在完全行使之前不會到期。普通認股權證的行使價格為每股 1.39 美元，發行後可行使，並將在首次行使日期的第五個週年到期。</p>
</div><p>The transactions closed on January 6, 2026, with approximately $8.0 million aggregate gross proceeds. The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working capital.</p>
<div class="lb-trans"><p>交易於 2026 年 1 月 6 日完成，約獲得 800 萬美元的總毛收益。公司預計將利用此次發行的淨收益以及現有現金用於一般企業用途和營運資金。</p>
</div><p>&#34;The successful closing of this financing underscores the continued investor support for our clinical vision and provides Estrella with additional resources to pursue our clinical objectives,&#34; said Dr. Cheng Liu, President and Chief Executive Officer of Estrella. &#34;We are well-positioned to advance our lead program, EB103, through its Phase II trial and towards key value-inflection points. We believe this is a critical step in developing our ARTEMIS® T-cell therapies for patients who are not eligible for currently marketed therapies.&#34;</p>
<div class="lb-trans"><p>“此次融資的成功完成凸顯了投資者對我們臨牀願景的持續支持，併為 Estrella 提供了額外資源，以追求我們的臨牀目標，” Estrella 的總裁兼首席執行官劉成博士表示。“我們已做好充分準備，推動我們的主導項目 EB103 進入第二階段試驗，並朝着關鍵的價值提升點邁進。我們相信這是為不符合當前市場療法的患者開發我們的 ARTEMIS® T 細胞療法的關鍵一步。”</p>
</div><p><strong>Aegis Capital Corp. acted as exclusive placement agent for the offerings. Winston &amp; Strawn LLP acted as counsel to the Company. Sichenzia Ross Ference Carmel LLP acted as counsel to Aegis Capital Corp.</strong></p>
<div class="lb-trans"><p><strong>Aegis Capital Corp.擔任此次發行的獨家配售代理。Winston &amp; Strawn LLP 擔任公司的法律顧問。Sichenzia Ross Ference Carmel LLP 擔任 Aegis Capital Corp.的法律顧問。</strong></p>
</div><p>The securities described above (excluding the Common Warrants and the shares of common stock underlying the Common Warrants) were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283770), declared effective by the U.S. Securities and Exchange Commission (“SEC”) on December 19, 2024. The registered direct offering was made only by means of a prospectus, including a prospectus supplement, which is part of the effective registration statement.. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, on the SEC’s website at http://www.sec.gov or by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.</p>
<div class="lb-trans"><p>上述證券（不包括普通認股權證及其基礎的普通股）是根據美國證券交易委員會（“SEC”）於 2024 年 12 月 19 日宣佈生效的 S-3 表格的架構註冊聲明（文件編號 333-283770）進行的。註冊直接發行僅通過招股説明書進行，包括招股説明書補充，這是有效註冊聲明的一部分。最終招股説明書補充及其附帶招股説明書的電子副本可在 SEC 網站 http://www.sec.gov 上獲取，或通過聯繫 Aegis Capital Corp.，注意：承銷部，1345 Avenue of the Americas，27 樓，紐約，NY 10105，電子郵件：syndicate@aegiscap.com，或電話：+1 (212) 813-1010。</p>
</div><p>The offer and sale of the Common Warrants in the concurrent private placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or applicable state securities laws. Accordingly, the Common Warrants and underlying shares of common stock may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to a registration rights agreement with the investor, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock issuable upon exercise of the Common Warrants.</p>
<div class="lb-trans"><p>普通認股權證在同時進行的私募中的發行和銷售是非公開發行的交易，未根據 1933 年證券法（“證券法”）或適用的州證券法進行註冊。因此，普通認股權證及其基礎的普通股在美國不得重新發行或轉售，除非根據有效的註冊聲明或適用的證券法註冊要求的豁免。證券僅向合格投資者提供。根據與投資者的註冊權協議，公司已同意向 SEC 提交一份或多份註冊聲明，涵蓋根據普通認股權證行使後可出售的普通股。</p>
</div><p>Before investing in this offering, interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.</p>
<div class="lb-trans"><p>在投資此發行之前，感興趣的各方應全面閲讀招股説明書補充及其附帶招股説明書，以及公司向 SEC 提交的其他文件，這些文件已在該招股説明書補充及其附帶招股説明書中引用，提供有關公司及該發行的更多信息。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售要約或購買要約的徵求，也不構成在任何州或司法管轄區內進行這些證券的銷售，若在任何此類州或司法管轄區內的要約、徵求或銷售在註冊或資格之前是非法的。</p>
</div><p><strong>About Estrella Immunopharma, Inc.</strong></p>
<div class="lb-trans"><p><strong>關於 Estrella Immunopharma, Inc.</strong></p>
</div><p>Estrella is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases. Estrella’s mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and other diseases. To accomplish this mission, Estrella’s lead product candidate, EB103, utilizes Eureka’s ARTEMIS technology to target CD19, a protein expressed on the surface of almost all B-cell leukemias and lymphomas. Estrella is also developing EB104, which also utilizes Eureka’s ARTEMIS technology to target not only CD19, but also CD22, a protein that, like CD19, is expressed on the surface of most B-cell malignancies.</p>
<div class="lb-trans"><p>Estrella 是一家臨牀階段的生物製藥公司，開發針對 CD19 和 CD22 的 ARTEMIS T 細胞療法，以治療癌症和自身免疫疾病。Estrella 的使命是利用人類免疫系統的進化力量，改變與癌症和其他疾病作鬥爭的患者的生活。為實現這一使命，Estrella 的主打產品候選 EB103 利用 Eureka 的 ARTEMIS 技術，針對 CD19，這是一種幾乎在所有 B 細胞白血病和淋巴瘤表面表達的蛋白質。Estrella 還在開發 EB104，該產品同樣利用 Eureka 的 ARTEMIS 技術，不僅針對 CD19，還針對 CD22，這是一種與 CD19 相似，在大多數 B 細胞惡性腫瘤表面表達的蛋白質。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.</p>
<div class="lb-trans"><p>上述材料可能包含根據 1933 年證券法第 27A 條和 1934 年證券交易法第 21E 條（均已修訂）定義的 “前瞻性聲明”。前瞻性聲明包括所有不單純與歷史或當前事實相關的聲明，包括但不限於關於公司的產品開發和商業前景的聲明，並且可以通過使用 “可能”、“將”、“期望”、“項目”、“估計”、“預期”、“計劃”、“相信”、“潛在”、“應該”、“繼續” 或這些詞的否定形式或其他可比詞彙來識別。前瞻性聲明並不保證未來的行動或表現。這些前瞻性聲明是基於公司當前可獲得的信息及其當前計劃或預期，並且受到可能顯著影響當前計劃的多種風險和不確定性的制約。如果這些風險或不確定性中的一個或多個變為現實，或者基礎假設被證明不正確，實際結果可能與預期、相信、估計、期望、意圖或計劃的結果有顯著差異。儘管公司相信前瞻性聲明中反映的期望是合理的，但公司無法保證未來的結果、表現或成就。除非適用法律（包括美國的證券法）要求，否則公司不打算更新任何前瞻性聲明以使這些聲明與實際結果一致。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjAxMDYwMDk1NTZyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260106009556r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260106009556/en/</p>
<div class="lb-trans"><p>在 businesswire.com 上查看源版本：https://www.businesswire.com/news/home/20260106009556/en/</p>
</div><p>Investor Relations</p>
<div class="lb-trans"><p>投資者關係</p>
</div><p>Estrella Immunopharma, Inc.</p>
<div class="lb-trans"><p>Estrella Immunopharma, Inc.</p>
</div><p>IR@estrellabio.com</p>
<div class="lb-trans"><p>IR@estrellabio.com</p>
</div><p>Source: Estrella Immunopharma, Inc.</p>
<div class="lb-trans"><p>來源：Estrella Immunopharma, Inc.</p>
</div>

Estrella Immunopharma 宣佈完成 800 萬美元的註冊直接發行及同時進行的私募配售 | ESLA 股票新聞